🔗 Share this article

While America proceeds with sweeping revisions to its vaccination recommendations, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by questioning COVID-19 vaccines throughout the pandemic and has concentrated on potential deaths after Covid vaccination in her short time at the FDA.

Planned Changes to Childhood Vaccine Schedule

Public health authorities planned to announce major revisions to the childhood vaccination calendar earlier this month, aligning the US with Denmark’s vaccine program, sources say – a major change that would put the US out of alignment with many the world with little proof for improved outcomes. The announcement has been postponed until the coming year.

Instead of Vinay Prasad, Tracy Beth Høeg is listed to speak at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to lead the center this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a tighter collaboration between the pharmaceutical and biologics branches as Høeg and Prasad consolidate power at the regulatory agency – and it suggests a renewed priority upon reevaluating already-approved immunizations at the FDA.

Høeg has frequently advocated for ending some pediatric immunization guidelines in the US to become more similar to Denmark, a society with nationalized medicine and a citizenry about the size of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – typically the purview of Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Expertise

The appointee has little discernible background in medication creation, regulation or administrative roles, which has been customary for previous heads of the biologics center. She has served at the FDA as a key advisor to the commissioner and CBER since spring.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, stated Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a large organization. She is not an expert in industry regulation.”

Former commissioners of CBER would “be deeply familiar with laws and regulations and the research of medication creation”, commented Dr. Janet Woodcock. “Objectively, she doesn’t have the type of experience that prior appointees who headed the center have had.”

The drug center has an vast portfolio at the FDA, the former commissioner stated.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office authorizes numerous generic drugs. There’s a biosimilars program, OTC medication office and other areas, and each of these need to be supervised,” she said. “The area you neglect, that is precisely what that I always told people is going to bite you.”

There is also, a major management aspect to the job, which oversees more than 5,000 employees. “It is a massive leadership role, if you do it right,” Woodcock concluded.

Official Statement and Controversial Programs

When asked about concerns about Høeg’s credentials and whether this appointment signifies more teamwork among agency officials on immunizations, a representative said that the “inquiries are based on incorrect assumptions”.

“Her resume aligns with the functions of her position,” the official explained, citing the time Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg inherits the commissioner’s new fast-track approval initiative, a controversial rapid medication authorization process that apparently worried her former heads. “How are these medications being selected for this expedited pathway? Who takes the calls?” Howard said. “There’s a lot of secrecy going on at the FDA right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards laxer oversight of most medications, aside from vaccines.”

Public History on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if concerning, track record, some experts observe. She authored a research paper using unverified public submissions to determine the rate of myocarditis after COVID-19 immunization. She consulted for the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to indicate Covid vaccines are riskier than they are.

Included in her “wish list” for the incoming government encompassed changing rules for new vaccines and halting “optional” vaccines, she remarked after the election on a podcast. At the FDA, Dr. Høeg has according to sources proposed preventing young men from obtaining COVID-19 vaccinations.

“She’s an thorough true believer who begins with her beliefs and tailors the evidence to accommodate the science in a extremely misleading, fraudulent fashion,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other contrarians, {like|